secwatch.observer — SEC 8-K summary
======================================

Issuer:     AbbVie Inc. (ABBV)
CIK:        0001551152
Form:       8-K
Filed at:   2025-02-05T23:59:59+00:00
Accession:  0001104659-25-009673
Event type: debt
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud

AbbVie enters $3.0 billion revolving credit facility maturing in 2030
---------------------------------------------------------------------

- On January 30, 2025, AbbVie entered a $3.0 billion unsecured revolving credit agreement with JPMorgan Chase as agent.
- The new facility matures on January 30, 2030, and AbbVie had no borrowings outstanding on the effective date.
- AbbVie's existing $5.0 billion revolver maturing in March 2028 remains in effect, bringing total revolving capacity to $8.0 billion.
- Borrowings under the facility bear variable interest rates and are subject to customary covenants.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1551152/000110465925009673/0001104659-25-009673-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1551152/000110465925009673/tm255474d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-009673

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer